Aventis Offers Plan To Protect Shareholders From Sanofi Plavix Patent Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
The Aventis board also votes to enter into negotiations with Novartis, thereby satisfying one of Novartis’ two prerequisites for commencing merger talks. Aventis will “pursue discussions” with French and German authorities to address their concerns about an Aventis/Novartis deal.
You may also be interested in...
Aventis Warrant Proposal Rejected By France; Sanofi Considers Raising Bid
AMF decision clears one hurdle in path of Sanofi/Aventis merger, but Sanofi still needs to decide whether to sweeten its bid.
Aventis Warrant Proposal Rejected By France; Sanofi Considers Raising Bid
AMF decision clears one hurdle in path of Sanofi/Aventis merger, but Sanofi still needs to decide whether to sweeten its bid.
Aventis Sues To Block Sanofi Bid; Warns That “Synergies” Would Hit Hard In U.S.
New Jersey lawsuit notes that Sanofi projects significant savings from merger but is downplaying impact in France and Germany. Aventis continues no-holds-barred defense against Sanofi bid.